(M61.1) Myositis ossificans progressiva

More details coming soon

Icon
37 701 in individuals diagnosis myositis ossificans progressiva confirmed
Icon
2 274 deaths with diagnosis myositis ossificans progressiva
Icon
6% mortality rate associated with the disease myositis ossificans progressiva

Diagnosis myositis ossificans progressiva is diagnosed Men are 33.31% more likely than Women

25 129

Men receive the diagnosis myositis ossificans progressiva

321 (1.3 %)

Died from this diagnosis.

100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
12 572

Women receive the diagnosis myositis ossificans progressiva

1 953 (15.5 %)

Died from this diagnosis.

Risk Group for the Disease myositis ossificans progressiva - Men aged 25-29 and Women aged 65-69

Icon
In Men diagnosis is most often set at age 5-79, 85-89
Icon
Less common in men the disease occurs at Age 0-5, 80-84, 90-95+Less common in women the disease occurs at Age 0-1, 85-89, 95+
Icon
In Women diagnosis is most often set at age 0-84, 90-94

Disease Features myositis ossificans progressiva

Icon
Absence or low individual and public risk
Icon

Myositis ossificans progressiva - what does this mean

Myositis ossificans progressiva is an inherited disorder in which muscles and other tissues become replaced by bone, leading to progressive stiffness and loss of movement. it is caused by mutations in the acvr1 gene, which is responsible for producing a protein involved in bone formation. the disorder begins in childhood and is characterized by painful swellings in the muscles, which can eventually become completely ossified.

What happens during the disease - myositis ossificans progressiva

Myositis ossificans progressiva is a rare genetic disorder characterized by the formation of bone-like tissue in the muscles. it is caused by a mutation in the acvr1 gene, which encodes a bone morphogenetic protein receptor. this mutation leads to an over-activation of the receptor, resulting in increased bone morphogenetic protein signaling and the formation of ectopic bone in the muscles. this leads to the progressive formation of bone-like tissue in the muscles, leading to impaired mobility and other complications.

Clinical Pattern

More details coming soon

How does a doctor diagnose

  • Physical examination of joints and muscles
  • X-rays of affected joints and muscles
  • Blood tests to measure levels of calcium and phosphorus
  • MRI scan to identify any calcification
  • Genetic testing to identify mutations in the ACVR1 gene
  • Bone scan to detect any new bone formation

Treatment and Medical Assistance

Main goal: To reduce the progression of the disease and improve the quality of life of the patient.
  • Regular physical therapy to increase range of motion and prevent progressive joint contractures
  • Regular stretching and range of motion exercises
  • Regular monitoring of vital signs and laboratory tests
  • Assessment of nutritional status and dietary modifications
  • Pain management with medications such as non-steroidal anti-inflammatory drugs and muscle relaxants
  • Surgery to remove any ossified tissue and improve joint mobility
  • Use of orthopedic supports to reduce pain and improve function
  • Assessment of respiratory function and use of respiratory aids when necessary
  • Rehabilitation to improve strength, balance, and coordination
  • Assessment of cognitive and psychosocial functioning
  • Counseling and support to help with coping strategies
Icon
14 Days of Hospitalization Required
Icon
Average Time for Outpatient Care Not Established

Myositis ossificans progressiva - Prevention

Myositis ossificans progressiva can be prevented by avoiding trauma to the muscles, joints, and tendons, as well as avoiding activities that can cause repetitive strain or injury to the affected areas. early recognition and treatment of any potential injury is also important in preventing the progression of the disease.

Specified forms of the disease

(D14.0) Benign neoplasm: Middle ear, nasal cavity and accessory sinuses
(D14.1) Benign neoplasm: Larynx
(D14.2) Benign neoplasm: Trachea
(D14.3) Benign neoplasm: Bronchus and lung
(D14.4) Benign neoplasm: Respiratory system, unspecified